On April 13, 2019 Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, reported that preclinical research for its glutaminase inhibitor CB-839 will be shared as poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2018 in Chicago (Press release, Calithera Biosciences, APR 13, 2018, View Source [SID1234535242]). CB-839 is a potent, selective, orally bioavailable glutaminase inhibitor in Phase 2 trials. The company and its academic collaborators will highlight data of CB-839 in novel therapeutic combinations in preclinical models of selected cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Tumor metabolism is a novel therapeutic approach that exploits the way in which cancer cells utilize nutrients to grow and survive," said Susan Molineaux, PhD, President and Chief Executive Officer of Calithera. "CB-839, a novel glutaminase inhibitor, has the potential to be developed in combination with standard of care cancer therapeutics such as CDK4/6 or PARP inhibitors to improve patient outcomes."

Preclinical data will be presented by Ethan Emberley, PhD, in a poster titled, "The glutaminase inhibitor CB-839 synergizes with CDK4/6 and PARP inhibitors in preclinical models," on April 17, 2018 (Abstract #3509/6). Data will be presented demonstrating that CB-839 synergizes with the CDK4/6 inhibitor palbociclib in colorectal carcinoma, triple negative breast cancer (TNBC), and ER+ breast cancer cell lines, and enhances anti-tumor activity in both an ER+ breast cancer and a colorectal cancer (CRC) xenograft tumor model. CB-839 treatment in combination with the PARP inhibitors niraparib and talazoparib has synergistic anti-proliferative activity in TNBC, CRC, non-small cell lung carcinoma, ovarian and prostate cancer cells. In vivo, the combination of CB-839 with PARP inhibitors enhances anti-tumor activity compared to single agent treatment in a CRC tumor xenograft model. Two additional posters will be presented by academic collaborators:

Suppression of clear cell ovarian carcinoma growth by glutaminase-1 inhibitor as single agent and in combination with PARP-1 inhibitor
Abstract # LB-253/20
Presenter: T. Li, Laboratory of Othon Iliopoulos, Massachusetts General Hospital Tuesday April 17, 2018

Combination treatment with CB-839 and romidepsin induces apoptosis and suppresses cell viability in preclinical models of chondrosarcoma
Abstract #1329/7
Presenter: T.N. Sheikh, Laboratory of Gary Schwartz, Columbia University Monday, April 16, 2018

About CB-839

Calithera’s lead product candidate, CB-839, is a potent, selective, reversible and orally bioavailable inhibitor of glutaminase. CB-839’s onco-metabolism activity takes advantage of the unique metabolic requirements of tumor cells and cancer-fighting immune cells such as cytotoxic T-cells. It is currently being evaluated in Phase 2 clinical trials in multiple tumor types, in combination with standard of care agents

On April 13, 2018 VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, reported that the Company will participate in several upcoming events in the second quarter of 2018 (Press release, Vaximm, APR 13, 2018, View Source [SID1234525295]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AACR (American Association for Cancer Research) Annual Meeting 2018 April 14 – 18, 2018 Chicago, IL, USA

Poster #733 / 18: "Modulating T cell immunity in tumors by targeting PD‑L1 and neoantigens using a live attenuated oral Salmonella platform"
Poster Session: Vaccines 1
Sunday, April 15th, 1:00 PM – 5:00 PM

The poster summarizes the immunogenicity and anti-leukemia efficacy of VAXIMM’s oral T‑cell immunotherapy candidate VXM10 encoding variants of the murine PD-L1 protein. The animal study also describes the systemic immunogenicity of Salmonella-based polyepitope oral vaccines, supporting the design of Salmonella-based neoantigen vaccines.

The abstract is available here.

European Neoantigen Summit 2018
April 24 – 26, 2018
Amsterdam, The Netherlands

Presentation: "Fast and Cost-Effective Oral Delivery Technology of Personalized T-Cell Vaccines Based on a Live Attenuated Bacteria Platform"
Thursday, April 26th, 11:15 AM CEST

Dr. Heinz Lubenau, Chief Operating Officer of VAXIMM, will present the Company’s platform technology based on first-in-class oral T-cell activators using modified attenuated bacteria that can be readily adapted to target a wide range of cancer-related antigens.

Dr. Lubenau also will participate in the panel, "Advancing Manufacturing Practices for Personalized Cancer Vaccines" taking place on Thursday, April 26th at 2:45 PM CEST.

Bio€quity Europe
May 14 – 16, 2018
Ghent, Belgium

Dr. Lubenau will give a corporate presentation on Tuesday, May 15th at 11:40 AM CEST.

On April 13, 2018 Incyte Corporation (Nasdaq:INCY) reported that it has scheduled its first quarter 2018 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, May 1, 2018 (Press release, Incyte, APR 13, 2018, View Source;p=RssLanding&cat=news&id=2342471 [SID1234525296]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The schedule for the press release and conference call/webcast is as follows:

Q1 2018 Press Release:

May 1, 2018 at 7:00 a.m. ET

Q1 2018 Conference Call:

May 1, 2018 at 8:00 a.m. ET

Domestic Dial-In Number:

877-407-3042

International Dial-In Number:

201-389-0864

Conference ID Number:

13678858

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13678858.

The live webcast with slides can be accessed at www.incyte.com under For Investors, Events and Presentations and will be available for replay for 30 days.

On April 13, 2018 Menarini Ricerche reported that it will present on the latest preclinical studies of its phosphatidylinositol 3-kinase (PI3K) class I inhibitor MEN1611, in development for solid tumors, at the AACR (Free AACR Whitepaper) Annual Meeting 2018, which will take place on April 14-18, 2018, in Chicago, Illinois, USA (Press release, Menarini, APR 13, 2018, View Source [SID1234531254]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The results of these preclinical studies will be described in two posters. The first one, entitled "MEN1611, a novel α-selective PI3K inhibitor in solid tumors", demonstrates the in-vitro and in-vivo antitumor activity of MEN1611, showing synergistic effects in combination with a number of targeted therapies in cell lines and patient-derived xenograft models of different tumor types. The second poster, entitled "The role of MEN1611, a class I PI3-Kinase (PI3K) inhibitor, in reprogramming the pro-tumoral inflammatory environment", investigates the role of MEN1611 in targeting inflammatory cells of the tumor microenvironment, through its ability to inhibit the PI3Kϒ isoform expressed by myeloid cells.

The results from Menarini Ricerche’s R&D programs will be presented in the following poster sessions: "MEN1611, a novel α-selective PI3K inhibitor in solid tumors" Abstract no. 2160, will take place on Monday, April 16, between 1:00PM – 5:00PM, during the session "Translational Therapeutics in Cancer Models 2" in the McCormick Place South, Exhibit Hall A, Poster Section 7, Poster Board #15.

"The role of MEN1611, a class I PI3-Kinase (PI3K) inhibitor, in reprogramming the pro-tumoral inflammatory environment" Abstract no. 2145, will take place on Monday, April 16, between 1:00PM – 5:00PM, during the session "The Metastatic Microenvironment" in the McCormick Place South, Exhibit Hall A, Poster Section 6, Poster Board #30

About MEN1611

MEN1611 is a novel orally available PI3-Kinase class I selective inhibitor, targeting with nanomolar potency the mutant PI3Kα isoforms and PI3Kϒ. The results of the Phase I study showed that MEN1611 was well tolerated and the maximum tolerated dose was determined. MEN1611 will enter this year a combination Phase IB study in breast cancer patients carrying mutations in the PI3K gene.

On April 13, 2018 Bristol-Myers Squibb Company (NYSE: BMY) and Illumina, Inc. (NASDAQ: ILMN) reported a collaboration that will utilize Illumina’s next-generation sequencing (NGS) technology to develop and globally commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb’s oncology portfolio (Press release, Bristol-Myers Squibb, APR 13, 2018, View Source [SID1234525302]). The companies plan to develop a diagnostic version of the Illumina TruSight Oncology 500 assay to measure potentially predictive genomic biomarkers, including Tumor Mutation Burden (TMB). Illumina’s TruSight Oncology 500 assay is being developed to detect most of the known biomarkers for oncology therapeutics, including TMB and Microsatellite Instability for immunotherapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Through our deep understanding of cancer biology and emerging research, we recognize the importance for physicians to know each patient’s biomarker status to help fight their cancer in a more personalized way," said Saurabh Saha, M.D., Ph.D., Senior Vice President, Global Head of Translational Medicine, Bristol-Myers Squibb. "We are excited to partner with Illumina to pursue development of diagnostics that can help predict which patients will have the potential to benefit most from our immunotherapies."

"The identification of biomarkers for targeted therapies is emerging as a key part of a cancer patient’s journey, from treatment selection through response monitoring and allows physicians to follow the evolution of a patient’s tumor over time," said Garret Hampton, Ph.D., Executive Vice President of Clinical Genomics at Illumina. "Next-generation sequencing assays, such as a companion diagnostic (CDx) version of TruSight Oncology 500, are ideally suited to the comprehensive interrogation of a patient’s cancer. With BMS’ leading position in immunotherapy development, we see tremendous promise in this partnership to co-develop next-generation sequencing-based diagnostics that can identify effective therapeutic combinations and provide global access to these targeted drugs."

Cancer immunotherapy works by helping the immune system mount an anti-cancer response, a process that depends in part on the recognition of cancer-specific proteins called neoantigens. Bristol-Myers Squibb’s clinical development program includes 24 clinical-stage molecules designed to target different immune system pathways across more than 50 types of cancers, and through its translational capabilities, has identified a number of potentially predictive biomarkers, including PD-L1, TMB, MSI-H/dMMR and LAG-3.